Pragmatic clinical trials to optimise immunotherapeutic interventions for patients with refractory cancers

Grantavia

P

^Beta

We use essential, analytics, and advertising cookies to improve the experience, measure usage, and optimize campaigns.

Learn more at Privacy Policy · Terms of Service · Cookie Policy

Description

Europe

Health & Life Sciences•100% • 22.2M€

Open — Sep 15 (100d)

Dates & Deadlines

Publication Date

Not defined

Opening Date

February 10, 2026

Application Phases

Deadline

September 15, 2026 at 06:00 PM

100 days left

Financial Details

Non-Refundable

Maximum Funding Rate

100%

Budget

22.2M€

Eligible Project Value

Up to 8M€

Maximum Duration

60 months

Criteria & Documents

Eligible Expenses

●Personnel Costs
●Travel costs
●Equipment costs
●Other goods, works and services costs
●Subcontracting
●Indirect Costs

Access Conditions

●Legal entities from EU Member States and Associated Countries
●Consortium must include partners from at least three different EU Member States or Associated Countries
●Compliance with general and specific admissibility and eligibility criteria

Selection Criteria

●Excellence (scientific and technical merit)
●Impact (contribution to policy and partnership KPIs)
●Quality and efficiency of implementation

Mandatory Information

●Application form (Part A and Part B)
●Budget

EU Programme Details

Call ID: HORIZON-MISS-2026-02-CANCER-03
Expected Projects: 3 projects

Funding Rate

100%

Budget

22.2M€

Days Left

100

Sep 15

Curated by

Maria Macedo

Eligibility

Eligible Sectors

Health & Life Sciences

Company Sizes

MicroSMESmall Mid-CapMid-CapLargePrivate non-profit entitiesPublic entities

Application Mode

Consortium / Copromotion

Official Links

Official Regulation

Cookies

Application Phases

Eligible Expenses

Access Conditions

Selection Criteria

Mandatory Information